Fedor Sysonov

Mr. Fedor Sysonov


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2024 in Cells
Verified
Journal Article
Open access
PDF file
VSVadim Valeryevich Shindyapin
Vadim Valeryevich Shindyapin
EGEkaterina Gubernatorova
Ekaterina Gubernatorova
EGEkaterina A. Gorshkova
Ekaterina A. Gorshkova
NCNelya Chicherina
Nelya Chicherina
FSFedor Sysonov
Fedor Sysonov
MDMarina S. Drutskaya
Marina S. Drutskaya
Malignant pleural mesothelioma is a neoplasm that is often detected late due to nonspecific symptoms. This study utilized NSG-SGM3 mice to examine interactions between a human-derived mesothelioma reporter cell line (MZT-Luc2-mCherry) and the host’s myeloid compartment. Tumor growth was assessed using optical tomography, while cytokine/chemokine production was analyzed via multiplex assay. Histological and immunohistochemical analyses validated the epithelioid mesothelioma phenotype. In vitro mesothelioma cells secreted factors associated with myeloid cell chemoattraction and functions supporting the previously reported myeloid-biased secretory phenotype. In line with this, post-engraftment analysis revealed increased neutrophil-like Ly6G+ populations and decreased Ly6C+ inflammatory monocytes in the blood of tumor-bearing mice. Significant Ly6G+ cell infiltration was observed in the tumor, while CD11b+ myeloid cells were localized primarily in the tumor periphery. Tumor lysates showed increased levels of neutrophil chemoattractants and G-CSF, suggesting a previously not reported role of neutrophils in mesothelioma progression. This novel model provides a platform for studying mesothelioma–host interactions, focusing on the myeloid compartment. It may also serve as a tool to facilitate the development of new therapeutic strategies targeting myeloid cell-mediated mechanisms in mesothelioma.

29 August 2026 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
FSFedor Sysonov
Fedor Sysonov
EGEkaterina A. Gorshkova
Ekaterina A. Gorshkova
KMKonstantin E. Menshikov
Konstantin E. Menshikov
MDMarina S. Drutskaya
Marina S. Drutskaya
SNSergey A. Nedospasov
Sergey A. Nedospasov
EGEkaterina Gubernatorova
Ekaterina Gubernatorova
Acute liver failure (ALF) is a severe pathological condition with high mortality, arising from diverse etiologies and involving multiple pathogenetic mechanisms. ALF is often accompanied by multi-organ failure due to infectious complications. Because of disease’s rapid progression, clinical studies of ALF remain limited, making the search for novel therapeutic strategies targeting specific molecular pathways and biochemical cascades a pressing task. Preclinical in vivo models are unique tools for reproducing individual aspects of ALF development. However, there is still no consensus on the gold-standard experimental animal model that fully captures ALF pathogenesis. This review systematically categorizes existing mouse models of ALF, outlining their advantages and with respect to the translational applicability of the data obtained. Among these models, we highlight the LPS/D‑GalN model as the most reliable in reproducing key stages of ALF development complicated by bacterial infection. Using this model as an example, we describe the known stages of pathogenesis, supported by the experiments with pharmacologically active substances and the use of various genetically modified mouse lines. Finally, special attention is given to the intestine as an organ that sustains significant damage during ALF progression in both clinical cases and most animal models.

Verified
Journal Article
Open access
PDF file
NCNelya Chicherina
Nelya Chicherina
EGEkaterina Gubernatorova
Ekaterina Gubernatorova
ONOlga Namakanova
Olga Namakanova
FSFedor Sysonov
Fedor Sysonov
EGEkaterina A. Gorshkova
Ekaterina A. Gorshkova
MDMarina Drutskaya
Marina Drutskaya
Fibrosis is a pathological form of tissue remodeling driven by excessive deposition of extracellular matrix (ECM). Unlike physiological tissue repair, fibrosis arises from persistent myofibroblast activation and unresolved inflammation. Chronic inflammation can both initiate fibrotic remodeling and be sustained by the resulting tissue alterations, supporting the view of fibrosis as an immune-mediated process. Fibrogenesis is fundamentally shaped by interactions between macrophages and fibroblasts. Polarized macrophages can modulate fibroblast activity and promote their differentiation into myofibroblasts. IL-6 is an important mediator of macrophage–fibroblast communication and has been implicated in fibrotic diseases affecting multiple organs. Notably, the effects of IL-6 are highly context-dependent. During acute injury, IL-6 can promote tissue repair by stimulating epithelial proliferation and angiogenesis, whereas persistent IL-6 signaling in chronic inflammation can become a major driver of fibrosis. IL-6 is also a prominent component of the senescence-associated secretory phenotype (SASP), providing a mechanistic link between fibrosis, cellular senescence, and inflammaging. In this review, we provide an integrated overview of the role of IL-6 in macrophage–fibroblast interactions during pulmonary fibrogenesis, with particular emphasis on its context-dependent functions at the interface between tissue repair and pathological tissue remodeling. We also discuss current therapeutic strategies aimed at targeting IL-6 signaling.